Introduction
Candidaemia is the most frequent fungal infection in hospitalized patients and is associated with significant mortality and prolonged hospital stay. 1 Although Candida albicans continues to predominate, the emergence of non-albicans Candida species as a cause of bloodstream infection (BSI) has been reported in all surveillance programmes, 1 including the large prospective survey performed in Europe by the European Confederation of Medical Mycology (ECMM) (unpublished data). This emergence is of special concern because of the virulence of these species in immunocompromised patients, and the occurrence of resistance to currently available antifungals. 2 Non-albicans Candida species accounted for 41% of the episodes of Candida BSI reported during the ECMM survey of candidaemia performed in one Italian region by the Federazione Italiana di Micopatologia Umana e Animale (FIMUA). 3 The in vitro susceptibility to the antifungals amphotericin B, flucytosine, fluconazole, itraconazole, voriconazole and posaconazole of 261 non-albicans Candida bloodstream strains isolated during this survey is reported. Resistance was correlated with the underlying conditions associated with infection and with previous antifungal therapy. The strains received by the coordinating centre were subcultured on Chromagar Candida medium (CHROMagar Microbiology, Paris, France) to ensure viability and purity.
Materials and methods

Isolates
Yeast identification was checked by morphology evaluation on potato-carrot-ox gall agar, and analysis of the biochemical patterns by ID 32 (bioMérieux, Roma, Italy). Isolates were stored as suspensions in distilled water at room temperature until needed.
Susceptibility testing
The antifungals tested were fluconazole (Pfizer Central Research, Sandwich, UK), itraconazole (Janssen Research Foundation, Beerse, Belgium), voriconazole (Pfizer), posaconazole (Schering-Plough Research Institute, Kenilworth, NJ, USA), flucytosine (Sigma-Chemical, Milano, Italy) and amphotericin B.
Susceptibility to amphotericin B was determined using Etest strips (AB Biodisk, Solna, Sweden) on Antibiotic medium 3 (Difco Laboratories, Detroit, MI, USA).
Susceptibility to flucytosine and azoles was determined using a broth microdilution method described by the NCCLS. 4 Testing was conducted in RPMI 1640 without sodium bicarbonate (Sigma-Chemical), buffered to pH 7.0 with 0.165 M MOPS (Sigma-Chemical) and supplemented with 2% glucose and 0.03% L-glutamine (Sigma-Chemical). C. parapsilosis ATCC 22019 was used as the quality control strain.
The interpretative breakpoints suggested in the NCCLS document were adopted.
Results and discussion
MICs for C. parapsilosis ATCC 22019 were within the expected range.
Amphotericin B and flucytosine were very active against the 261 non-albicans Candida isolates from blood.
Testing for susceptibility to amphotericin B, performed using Etest strips, showed MIC endpoints <0.50 mg/L in all the isolates tested.
MICs of flucytosine, at which 50% (MIC 50 ) and 90% (MIC 90 ) of the strains were inhibited, were ≤0.25 and 2 mg/L, respectively. Resistance (MIC ≥32 mg/L) was detected in 19 isolates, including 13 C. tropicalis, two C. glabrata, two C. krusei, one C. parapsilosis and one C. pelliculosa. Overall, the rate of flucytosine resistance (7.3%) was higher compared with that reported in other studies. 5, 6 The high prevalence of resistance among C. tropicalis (13/44, 30%) and C. krusei (2/6) is noteworthy and consistent with the relatively poor susceptibility of these species observed in the first studies on this drug. 7 A large recent investigation confirms the data on C. krusei, but reports resistance of only 8% among C. tropicalis. 6 None of the patients infected by flucytosine-resistant Candida was HIV positive and none had received flucytosine in the previous 2 weeks. Surgery (12/19) and cancer (9/19) were the main underlying conditions associated with resistance. However, there is a frequent association of surgery and cancer with C. tropicalis, which has a high level of resistance to flucytosine (71% and 58% of C. tropicalis BSI occurred in surgical and cancer patients, respectively); 3 thus these conditions together may be responsible for the resistance. Resistance among C. tropicalis isolates occurred in patients hospitalized in 11 different institutions, ruling out the presence of a unique flucytosine-resistant strain infecting all patients.
The patterns of in vitro susceptibility to azoles are reported in a continuous fashion (Table 1) .
In addition to the eight isolates belonging to intrinsically fluconazoleresistant species (C. krusei, C. inconspicua and C. norvegensis), three C. glabrata and two C. tropicalis isolates showed resistance to this azole (MIC ≥64 mg/L). Overall the frequency of resistance to fluconazole was low (13/261, 5%). In particular the rate among C. glabrata isolates (3/80, 3.75%) was lower than that reported in other surveillance studies, in which it ranged from 7% to 40%. 1 Resistance occurred in 4% (10/251) of HIV-negative and in 30% (3/10) of HIV-positive patients with non-albicans Candida BSI included in our series (P = 0.14). Two patients had undergone vascular surgery and four surgery of the alimentary tract. Two patients had a solid tumour and one leukaemia. Resistance occurred in patients hospitalized in nine different institutions. Four of the HIV-negative patients and one HIV-positive subject received fluconazole during the 2 weeks preceding candidaemia.
Overall, 52% and 85% of isolates were inhibited by 0.06 and 0.25 mg/L of itraconazole, respectively. Elevated MICs (≥1 mg/L) were detected in seven isolates, that is two C. tropicalis strains, both fluconazole-resistant, and five C. glabrata strains, two of which were susceptible to a specific dose of fluconazole. None of the patients infected by these strains received azole antifungals during the 14 day period prior to candidaemia.
As reported in other studies, 8, 9 both voriconazole and posaconazole were very active against non-albicans Candida isolates (MIC 90 , 0.25 mg/L). C. glabrata and C. tropicalis were the least susceptible species.
Cross-resistance among fluconazole and other triazoles was a rare event. In most cases only an increase in the MIC endpoints of the other azoles was observed: three fluconazole-resistant C. glabrata strains were inhibited by itraconazole at 0.5 mg/L and by voriconazole and posaconazole at 1-2 mg/L. Out of the two C. tropicalis isolates, one was inhibited by itraconazole, voriconazole and posaconazole at concentrations of 1-2 mg/L, the other at concentrations ≥16 mg/L. Intrinsically, fluconazole-resistant Candida species showed no cross resistance: MICs of itraconazole, voriconazole and posaconazole for C. krusei, C. norvegensis and C. inconspicua isolates were ≤0.5 mg/L.
In conclusion, as seen in other studies, 1, 5, 10 resistance to antifungal agents is a rare finding in non-albicans Candida species isolated from blood. However, in fungaemias caused by C. tropicalis, C. glabrata and C. krusei these species are characterized by a high prevalence of resistance to fluconazole and flucytosine. In addition, fluconazole resistance should be suspected in breakthrough infections previously treated with azoles. In clinical practice, long-term use of fluconazole is required mainly in advanced stages of AIDS, in empirical treatment of candidosis in cancer and surgical patients, and as prophylaxis. As cross-resistance to other azoles is rare, fluconazole resistance does not necessarily rule out the use of newer azoles, such as voriconazole and posaconazole as potential treatment options for serious Candida infections.
Geographic variations of Candida species as the cause of BSIs and differences in the prevalence of resistance demonstrate the importance of local surveillance studies. 2 Because the current limitations of in vitro susceptibility testing do not yet allow routine application of the tests, careful mycological identification at the species level of Candida isolates recovered from blood, together with information on the prevalence of more resistant species and on overall antifungal susceptibility patterns obtained during local surveillance studies, are needed to help clinicians make treatment decisions. itraconazole  2  3  6  10  11  --------voriconazole  1  7  10  10  10  11 -------posaconazole  1  4  7  11  ---------C. pelliculosa (8)  fluconazole  -----1  2  5  8 ----itraconazole  --3  6  8  --------voriconazole  -1  4  8  ---------posaconazole  ---2  7 8 -------C. krusei (6) fluconazole --------1  1  2  6  -itraconazole  1  2  2  3  6  --------v o r i c o n a z o l e  1  1  2  2  6  --------posaconazole  1  1  1  6  --------C. lusitaniae (5)  fluconazole  ---5  ---------itraconazole  2  5  -----------voriconazole  4  5  -----------posaconazole  5  ------------C. lipolytica (2)  fluconazole  ----1  1  2 ------itraconazole  1  2  -----------voriconazole  2  ------------posaconazole  -1  2  ---------- 
